Brief: Ascentage Pharma Group International Updates On Clinical Development Of APG-2575

Ascentage Pharma International

10/12/2020 24:40

Dec 10 (Reuters) - Ascentage Pharma Group International
 6855.HK :
    * UPDATES ON CLINICAL DEVELOPMENT OF APG-2575
    * PRELIM CLINICAL STUDY RESULTS SHOW OBJECTIVE RESPONSE RATE
OF
70% HAS BEEN REACHED IN EVALUABLE PATIENTS
    * APG-2575 GRANTED 3 ORPHAN DRUG DESIGNATIONS BY U.S. FDA
    * APG-2575 GRANTED ODDS FOR TREATMENT OF CHRONIC LYMPHOCYTIC
LEUKEMIA, MULTIPLE MYELOMA, & WALDENSTRÖM MACROGLOBULINEMIA

Source text for Eikon:  urn:newsml:reuters.com:*:nHKS9J3zmp
Further company coverage:  6855.HK 

 ((Reuters.Briefs@thomsonreuters.com;))